ZIOPHARM Oncology Stock Forecast, Price & News

-0.05 (-1.87 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.55 million shs
Average Volume2.35 million shs
Market Capitalization$566.83 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOPHARM Oncology logo

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.41 out of 5 stars

Medical Sector

702nd out of 2,105 stocks

Pharmaceutical Preparations Industry

341st out of 832 stocks

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

Is ZIOPHARM Oncology a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than ZIOPHARM Oncology?

Wall Street analysts have given ZIOPHARM Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ZIOPHARM Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ZIOPHARM Oncology

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. During the same period in the previous year, the business posted ($0.09) earnings per share.
View ZIOPHARM Oncology's earnings history

How has ZIOPHARM Oncology's stock price been impacted by Coronavirus (COVID-19)?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP shares have increased by 3.5% and is now trading at $2.63.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZIOP?

5 analysts have issued 1 year target prices for ZIOPHARM Oncology's stock. Their forecasts range from $4.00 to $7.50. On average, they expect ZIOPHARM Oncology's stock price to reach $5.63 in the next twelve months. This suggests a possible upside of 113.9% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology
or view top-rated stocks among Wall Street analysts.

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Mr. Zuie-Chin Huang M.B.A., Exec. Chairman (Age 55, Pay $22.28k)
  • Ms. Heidi M. Hagen, Interim CEO, Principal Exec. Officer & Director (Age 52, Pay $69k)
  • Mr. Robert Hadfield, Chief Legal Officer & Sec. (Age 43, Pay $516.1k)
  • Dr. Eleanor de Groot, Exec. VP & GM of Cell Therapy (Age 52, Pay $488.98k)
  • Dr. Raffaele Baffa M.D., Ph.D., Chief Medical Officer (Age 60, Pay $242.83k)
  • Mr. Timothy M. Cunningham, Interim CFO & Principal Financial Officer (Age 59)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 65)
  • Ms. Lynn M. Ferrucci, Exec. VP of HR, Facilities, Admin. & IT
  • Christopher Taylor, VP of Investor Relations & Corp. Communications
  • Dr. Adam D. Levy M.B.A., Ph.D., Exec. VP of Investor Relations & Corp. Communications

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.68%), JPMorgan Chase & Co. (2.44%), Geode Capital Management LLC (1.64%), Northern Trust Corp (1.10%), Bank of New York Mellon Corp (0.46%) and D. E. Shaw & Co. Inc. (0.46%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology

Which major investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Morgan Stanley, Credit Suisse AG, Northern Trust Corp, Goldman Sachs Group Inc., Sargent Investment Group LLC, Bank of Montreal Can, and Rhumbline Advisers. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield.
View insider buying and selling activity for ZIOPHARM Oncology
or view top insider-selling stocks.

Which major investors are buying ZIOPHARM Oncology stock?

ZIOP stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Citigroup Inc., D. E. Shaw & Co. Inc., Rafferty Asset Management LLC, Geode Capital Management LLC, Renaissance Technologies LLC, UBS Group AG, and Squarepoint Ops LLC.
View insider buying and selling activity for ZIOPHARM Oncology
or or view top insider-buying stocks.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $2.63.

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of $566.83 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-79,980,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

ZIOPHARM Oncology employs 103 workers across the globe.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is

Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.